AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

Monday, November 12, 2012

AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

Details

Published on Monday, 12 November 2012 00:00

Written by Liz Highleyman

Jordan Feld from Toronto Western Hospital Liver Centre and colleagues evaluated the safety and efficacy of different combination regimens containing the second-generation HCV protease inhibitor danoprevir, the nucleoside HCV polymerase inhibitor mericitabine, ribavirin, and for some participants, pegylated interferon alfa-2a (Pegasys).

Danoprevir is boosted with a small amount of ritonavir (Norvir) to reach higher levels in the body.

View the results at HIV and Hepatitis

All AASLD Coverage @ HIV and Hepatitis

Highlights
Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.

HCV New Drugs

Risk Of Developing Liver Cancer After HCV Treatment

Monday, November 12, 2012